POSTOPERATIVE HORMONE THERAPY IN PATIENTS WITH ENDOMETRIOSIS AND UTERINE MYOMA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To investigate the efficiency of using the gonadotropin-releasing hormone agonist triptorelin 3.75 mg in the postoperative period according to the data available in Russian and foreign literature. Material and methods. The key words «triptorelin», «endometriosis», «uterine myoma», and «postoperative period» were used to search for literature sources in the Russian and foreign databases: elibrary, Medline/ PubMed, Embase, and CINAHL. Twenty-six sources were selected. Results. Women with uterine myoma and endometriosis have a high recurrence rate in the postoperative period. Different hormone therapy options, during which gonadotropin-releasing hormone agonists and, triptorelin 3.75 mg in particular, occupy one of the leading places, are used to rehabilitate these patients and to prevent a relapse. However, investigations dealing with this problem are now scarce. There is no uniform tactics in the rehabilitation of patients with uterine myoma and endometriosis. Conclusion. Gonadotropin-releasing hormone agonists and, triptorelin 3.75 mg in particular, are highly effective and may be recommended for use. However, whether individual therapy and rehabilitation tactics can be chosen calls for further investigation.

Full Text

Restricted Access

About the authors

Elena Grigorevna Khilkevich

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University

Email: e_khilkevich@oparina4.ru
leading researcher of General Surgery; professor of Department of Obstetrics, Gynecology, Perinatology and Reproductive Moscow 117997, Ac. Oparina str. 4, Russia

Olga Igorevna Yazykova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: o_yazykova@inbox.ru
intern of General Surgery Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Rogers P.A., D’Hooghe T.M., Fazleabas A., Gargett C.E., Giudice L.C., Montgomery G.W. et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod. Sci. 2009; 16(4): 335-46.
  2. Савельева Г.М., Бреусенко В.Г., ред. Гинекология. 3-е изд. М.: ГЭОТАР-Медиа; 2007.
  3. Тихомиров А.Л., Лубнин Д.М. Миома матки. М.: МИА; 2006
  4. Maclaran K., Agarwal N., Odejinmi F. Co-existence of uterine myomas and endometriosis in women undergoing laparoscopic myomectomy: risk factors and surgical implications. J. Minim. Invasive Gynecol. 2014; 21(6): 1086-90.
  5. Huang J.Q., Lathi R.B., Lemyre M., Rodriguez H.T., Nezhat C.H., Nezhat C. Coexistence of endometriosis in women with symptomatic leiomyomas. Fertil. Steril. 2010; 94(2): 720-3.
  6. Isono W., Wada-Hiraike O., Osuga Y., Yano T., Taketani V. Diameter of dominant leiomyoma is a possible determinant to predict coexistent endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012; 162(1): 87-90.
  7. Jacobson T.Z., Duffy J.M., Barlow D., Farquhar C., Koninckx P.R., Olive D. Laparoscopic surgery for subfertility associated with endometriosis. Cochrane Database Syst. Rev. 2010; (3): CD001398.
  8. Vercellini P., Crosignani P.G., Abbiati A., Somigliana E., Vigano P., Fedele L. The effect of surgery for symptomatic endometriosis: the other side of the story. Hum. Reprod. Update. 2009; 15(2): 177-88.
  9. Yoo E.H., Lee P.I., Huh C.Y., Kim D.H., Lee B.S., Lee J.K., Kim D. Predictors of leiomyoma recurrence after laparoscopic myomectomy. J. Minim. Invasive Gynecol. 2007; 14(6): 690-7.
  10. Reed S.D., Newton K.M., Thompson L.B., McCrummen B.A., Warolin A.K. The incidence of repeat’ uterine surgery following myomectomy. J. Women’s Health. 2006; 15(9): 1046-52.
  11. Буянова С.Н., Юдина Н.В., Гукасян С.А., Шеина Е.Н. Тактика ведения пациенток с миомой матки от раннего репродуктивного до постменопаузального возраста. Русский медицинский журнал. 2015; 23(1): 3-5
  12. Опыт применения бусерелина в гинекологической практике (сборник статей №2). М.: ФАРМ-СИНТЕЗ; 2003
  13. Тихомиров А.Л. Агонисты гонадотропных релизинг-гормонов в лечении миомы матки. Русский медицинский журнал. 2010; 18(4): 188-91
  14. Тихомиров А.Л. Современные принципы терапевтического лечения миомы матки. Эффективная фармакотерапия. 2015; 5: 56-60
  15. Chegini N., Kornberg L. Gonadotropin-releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma. J. Soc. Gynecol. Investig. 2003; 10(1): 21-6.
  16. Schindler A.E. Gonadotropin-releasing agonists for prevention of postoperative adhesions: an overview. Gynecol. Endocrinol. 2004; 19(1): 51-5.
  17. Almassinokiani F., Mehdizadeh A., Sariri E., Rezaei M., Almasi A., Akbari H. et al. Effects of simvastatin in prevention of pain recurrences after surgery for endometriosis. Med. Sci. Monit. 2013; 19: 534-9.
  18. Wong A.Y., Tang L. An open and randomized study comparing the efficacy of standard danazol and modified triptorelin regimens for postoperative disease management of moderate to severe endometriosis. Fertil. Steril. 2004; 81(6): 1522-7.
  19. Ferrero S., Abbamonte L.H., Giordano M., Ragni N., Remorgida V. Deep dyspareunia and sex life after laparoscopic excision of endometriosis. Hum. Reprod. 2007; 22(4): 1142-8.
  20. Kang J.L., Wang X.X., Nie M.L., Huang X.H. Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis. Gynecol. Obstet. Invest. 2010; 69(2): 73-7.
  21. Alborzi S., Hamedi B., Omidvar A., Dehbashi S., Alborzi S., Alborzi M. A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. Arch. Gynecol. Obstet. 2011; 284(1): 105-10.
  22. Сольский С.Я., Сольский В.С. Оценка эффективности комбинированного лечения наружного генитального эндометриоза. Журнал акушерства и женских болезней. 2009; 58(5): m79.
  23. Петракова С.А. Особенности прегравидарной подготовки больных с миомой матки: дисс.. канд. мед. наук. М.; 2009.
  24. Краснопольский В.И., Буянова С.Н., Логутова Л.С., Щукина Н.А., Юдина Н.В., Чечнева М.А. Миома матки вне и во время беременности. Клиника, диагностика, хирургическое лечение и реабилитация. Учебное пособие. М.; 2014.
  25. Фаткуллин И.Ф., Баканова А.Р. Антигестагены в адъювантной терапии после консервативной миомэктомии у пациенток репродуктивного возраста. Доктор.Ру. 2012; 7: 9-14.
  26. Blumenfeld Z., von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum. Reprod. Update. 2008; 14(6): 543-52.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies